公开(公告)号：US12128024B2

公开(公告)日：2024-10-29

申请号：US17072726

申请日：2020-10-16

申请人： GEORGETOWN UNIVERSITY

发明人： Richard Schlegel ,  Dan-Paul Hartmann ,  Astrid Baege

IPC分类号： C07D493/18 ,  A61K31/335 ,  A61K31/357 ,  A61K31/365 ,  A61K31/366 ,  A61K45/06 ,  A61P31/20

CPC分类号： A61K31/366 ,  A61K31/335 ,  A61K31/357 ,  A61K31/365 ,  A61K45/06 ,  A61P31/20 ,  C07D493/18 ,  A61K31/335 ,  A61K2300/00 ,  A61K31/365 ,  A61K2300/00

摘要： In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.

公开(公告)号：US12115208B2

公开(公告)日：2024-10-15

申请号：US16158928

申请日：2018-10-12

申请人： HIGH POINT UNIVERSITY

发明人： Meghan Scobee Blackledge ,  Patrick Andrew Vigueira ,  Heather B. Miller

IPC分类号： A61K38/14 ,  A61K31/335 ,  A61K31/553 ,  A61P31/04

CPC分类号： A61K38/14 ,  A61K31/335 ,  A61K31/553 ,  A61P31/04

摘要： Methods for treating a bacterial infection and for suppressing antibiotic resistance in a patient are described herein. Certain such methods generally involve administering an antibiotic and an adjuvant compound to a patient with a bacterial infection caused by Staphylococcus aureus, wherein the adjuvant compound comprises a fused tricyclic ring system with at least one halogen substituent. Compositions and kits containing such components are also described.

公开(公告)号：US20240316146A1

公开(公告)日：2024-09-26

申请号：US18260677

申请日：2022-01-07

申请人： Bexion Pharmaceuticals Inc.

发明人： Ray Takigiku ,  Darren P. Wolfe ,  Anne Mary Noonan ,  Robert Wesolowski ,  Charles A. Cruze, III ,  Gilles Hugues Tapolsky ,  Richard Charles Curry, III ,  Michael Gazda

IPC分类号： A61K38/17 ,  A61K9/127 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/282 ,  A61K31/335 ,  A61K31/337 ,  A61K31/381 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/69 ,  A61K31/7048 ,  A61K33/243 ,  A61K38/07 ,  A61K39/395 ,  A61K45/06 ,  A61K47/24 ,  A61P35/00

CPC分类号： A61K38/1709 ,  A61K9/127 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/282 ,  A61K31/335 ,  A61K31/337 ,  A61K31/381 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/69 ,  A61K31/7048 ,  A61K33/243 ,  A61K38/07 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/24 ,  A61P35/00

摘要： Disclosed herein are methods for reducing neuropathy and neuropathic symptoms and/or promoting neurogenesis, neuritogenesis, neuroprotection and neuroregeneration using saposin C-phospholipid compositions. Also disclosed are methods for treating cancer by administering a saposin C-phospholipid nanovesicle formulation and one or more antineoplastic agents or immune checkpoint inhibitors, and kits for the treatment of cancer comprising, in separate containers, (a) a saposin C-phospholipid pharmaceutical composition, and (b) a pharmaceutical composition containing an antineoplastic agent or a pharmaceutical composition containing an immune checkpoint inhibitor.

公开(公告)号：US12064442B2

公开(公告)日：2024-08-20

申请号：US17807487

申请日：2022-06-17

申请人： GLENMARK SPECIALTY S.A.

发明人： Neelima Khairatkar-Joshi ,  Abhay Kulkarni ,  Dinesh Pradeep Wale ,  Vikram M. Bhosale ,  Piyush Agarwal ,  Patrick Keohane ,  Sudeesh K. Tantry ,  Chad Oh

IPC分类号： A61K31/58 ,  A61K9/00 ,  A61K31/335 ,  A61K31/573 ,  A61M11/00 ,  A61M15/08 ,  A61P11/02 ,  A61P27/14 ,  A61P37/08

CPC分类号： A61K31/58 ,  A61K9/0043 ,  A61K31/335 ,  A61K31/573 ,  A61P11/02 ,  A61P27/14 ,  A61P37/08 ,  A61M11/007 ,  A61M15/08

摘要： The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

公开(公告)号：US12054493B2

公开(公告)日：2024-08-06

申请号：US17143326

申请日：2021-01-07

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC分类号： C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/00 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C317/44 ,  C07C323/42 ,  C07C323/62 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

CPC分类号： C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/001 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C317/44 ,  C07C323/42 ,  C07C323/62 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04 ,  C07B2200/05 ,  C07B2200/07 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/44 ,  C07C2602/46 ,  C07C2603/74

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240201204A1

公开(公告)日：2024-06-20

申请号：US17790480

申请日：2021-01-07

申请人： University Hospitals Cleveland Medical Center

发明人： Andrew A. Pieper ,  Min-Kyoo Shin ,  Edwin Vazquez-Rosa

IPC分类号： G01N33/68 ,  A61K31/335 ,  A61K31/403 ,  A61K31/603

CPC分类号： G01N33/6896 ,  A61K31/335 ,  A61K31/403 ,  A61K31/603 ,  G01N33/6854 ,  G01N2333/4709 ,  G01N2800/52

摘要： In one aspect, disclosed herein is a method of diagnosing and/or prognosing a neurodegenerative disease in a subject, the method comprising: obtaining a plasma or blood sample from a subject; and detecting a level of acetylated Tau in the plasma or blood sample, wherein a level of acetylated Tau that is at least 25% or 50% higher than a control level in a healthy subject indicates that the subject has a neurodegenerative disease such as traumatic brain injury.

公开(公告)号：US20240156840A1

公开(公告)日：2024-05-16

申请号：US18392033

申请日：2023-12-21

申请人： GLENMARK SPECIALTY S.A.

发明人： Neelima KHAIRATKAR-JOSHI ,  Abhay KULKARNI ,  Dinesh Pradeep WALE ,  Vikram M. BHOSALE ,  Piyush AGARWAL ,  Patrick KEOHANE ,  Sudeesh K. TANTRY ,  Chad OH

IPC分类号： A61K31/58 ,  A61K9/00 ,  A61K31/335 ,  A61K31/573 ,  A61P11/02 ,  A61P27/14 ,  A61P37/08

CPC分类号： A61K31/58 ,  A61K9/0043 ,  A61K31/335 ,  A61K31/573 ,  A61P11/02 ,  A61P27/14 ,  A61P37/08 ,  A61M11/007

摘要： The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

公开(公告)号：US11865103B2

公开(公告)日：2024-01-09

申请号：US17468274

申请日：2021-09-07

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Alagramam N. Kumar ,  Suhasini Gopal Ramanujam

IPC分类号： A61K31/12 ,  A61K31/34 ,  A61K31/335 ,  A61K31/435 ,  A61K33/00 ,  A61K31/357 ,  A61P27/16 ,  A61K31/343

CPC分类号： A61K31/357 ,  A61K31/343 ,  A61P27/16

摘要： A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.

公开(公告)号：US20230285689A1

公开(公告)日：2023-09-14

申请号：US18309963

申请日：2023-05-01

申请人： Glenmark Specially S.A.

发明人： Ulhas R. DHUPPAD ,  Ashok KATKURWAR ,  Yashwant GUPTA ,  Rajesh ANKAM ,  Chandrakant DHATRAK ,  Neelima KHAIRATKAR-JOSHI ,  Abhay KULKARNI ,  Dinesh Pradeep WALE ,  Vikram Mansingh BHOSALE ,  Piyush AGARWAL ,  Patrick KEOHANE ,  Sudeesh K. TANTRY ,  Chad OH

IPC分类号： A61M11/00 ,  A61K31/58 ,  A61K31/335 ,  A61K9/00 ,  A61K47/38 ,  A61K47/02 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  A61P37/08 ,  A61M15/00 ,  A61M15/08 ,  A61M31/00 ,  B05B15/30 ,  A61K47/36

CPC分类号： A61M11/007 ,  A61K31/58 ,  A61K31/335 ,  A61K9/0043 ,  A61K47/38 ,  A61K47/02 ,  A61K47/183 ,  A61K47/24 ,  A61K47/26 ,  A61P37/08 ,  A61K47/186 ,  A61M15/0065 ,  A61M15/08 ,  A61M31/00 ,  B05B15/30 ,  A61K47/36 ,  A61M2210/0618 ,  B05B11/0037

摘要： A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.

公开(公告)号：US20230255922A1

公开(公告)日：2023-08-17

申请号：US18141170

申请日：2023-04-28

申请人： United Therapeutics Corporation

发明人： Ken PHARES ,  Hitesh BATRA ,  Liang GUO ,  Adam Marc SILVERSTEIN

IPC分类号： A61K31/27 ,  A61K31/216 ,  A61K31/335 ,  A61K31/222 ,  A61P9/12 ,  A61K9/00 ,  A61K31/192 ,  A61K31/265

CPC分类号： A61K31/27 ,  A61K31/216 ,  A61K31/335 ,  A61K31/222 ,  A61P9/12 ,  A61K9/0019 ,  A61K31/192 ,  A61K31/265

摘要： Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.